NCT00082602

Data

{
  "briefSummary": "The purpose of this study is to evaluate the safety and tolerability of an extended release formulation of the drug galantamine using a rapid dose escalation regimen.",
  "completionDate": "2005-04",
  "conditions": [
    "Alzheimer's Disease"
  ],
  "enrollmentCount": 83,
  "enrollmentType": "ACTUAL",
  "nctId": "NCT00082602",
  "phase": "PHASE3",
  "sponsorId": "johnson-johnson-pharmaceutical-research-development-l-l-c",
  "startDate": "2004-05",
  "status": "COMPLETED",
  "studyType": "INTERVENTIONAL",
  "title": "Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease",
  "url": "https://clinicaltrials.gov/study/NCT00082602"
}

History in this collection

1. addedv1.0.0Jun 12, 2026this version